| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
|
| Product Name: | XRP44X | | Synonyms: | XRP44X;1-(3-Chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]piperazine;[4-(3-Chlorophenyl)-1-piperazinyl](3-methyl-1-phenyl-1H-pyrazol-5-yl)-methanone;[4-(3-Chlorophenyl)piperazin-1-yl](5-methyl-2-phenyl-2H-pyrazol-3-yl)methanone;(4-(3-Chlorophenyl)piperazin-1-yl)(3-methyl-1-phenyl-1H-pyrazol-5-yl)methanone;Ras-Net (Elk-3) Pathway Inhibitor, XRP44X;Piperazine,1-(3-chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]-;[4-(3-chlorophenyl)piperazin-1-yl]-(5-methyl-2-phenylpyrazol-3-yl)methanone | | CAS: | 729605-21-4 | | MF: | C21H21ClN4O | | MW: | 380.87 | | EINECS: | 684-708-0 | | Product Categories: | | | Mol File: | 729605-21-4.mol |  |
| | XRP44X Chemical Properties |
| Melting point | 136-140 0C | | Boiling point | 591.1±50.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: ≥20mg/mL | | pka | 1.79±0.20(Predicted) | | form | White solid | | color | white to off-white | | InChI | 1S/C21H21ClN4O/c1-16-14-20(26(23-16)18-7-3-2-4-8-18)21(27)25-12-10-24(11-13-25)19-9-5-6-17(22)15-19/h2-9,14-15H,10-13H2,1H3 | | InChIKey | NPHPNBGYPKBDDB-UHFFFAOYSA-N |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | XRP44X Usage And Synthesis |
| Uses | XRP44X, is a Ras-Net (Elk-3) pathway inhibitor; tubulin polymerization inhibitor Colchicine binding site.XRP44X is used as an anti-cancer drug targeting epidermal growth factor receptor. | | Definition | ChEBI: [4-(3-chlorophenyl)-1-piperazinyl]-(5-methyl-2-phenyl-3-pyrazolyl)methanone is a member of piperazines. | | General Description | A cell-permeable pyrazole compound that is shown to prevent in vitro tubulin polymerization (IC50 = 0.2 μM) by targeting Colchicine (Cat. No. 234115) binding site (Kd = 0.3 μM) in cell-free assays and induce blebs formation in HUVEC cultures by perturbing both tubulin microtubles and actin cytoskeleton structures. Unrelated to its effects on actin and tubulin filaments, XRP44X is also reported to block the activations of Ras and its downstream effector molecules, such as Raf, MEK, Erk, Rsk, and Net (Elk-3/SAP-2/Erp), upon FGF-2 (Cat. No. 341595) stimulation. Potently inhibits the growth of HUVEC, NIH3T3, as well as 9 other cancer cell lines in antiproliferation assays (IC50 ≤11.3 nM). | | Biochem/physiol Actions | XRP44X is a Ras-Net (Elk-3) pathway inhibitor; tubulin polymerization inhibitor Colchicine binding site. | | in vivo | XRP44X may have therapeutic potential for refractory asthma[1].
XRP44X, an inhibitor of Ras/Erk activation of the transcription factor Elk3, inhibits tumor growth and metastasis in mice. XRP44X inhibits tumor growth and metastasis in nude mice. XRP44X decreases the growth of tumours and the formation of metastases in nude mice[2]. | Animal Model: | Male nude mice (BALB/c nu/nu)[2] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; treated daily for 6 days | | Result: | Inhibited cell tumor formation by xenografts in nude mice. |
| | IC 50 | Ras: 10 nM (IC50) |
| | XRP44X Preparation Products And Raw materials |
|